Patents by Inventor Toshio Miyata

Toshio Miyata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220143185
    Abstract: Methods of treating a metabolic disorder comprising orally administering to the patient a small molecule inhibitor of plasminogen activator inhibitor 1 (PAI-1) are described. The treatment with the PAI-1 inhibitor changes at least one metabolic measurement of the patient such as fasting glucose, fasting plasma insulin and fasting plasma LDL when compared to the metabolic measurement of the patient in an untreated condition. The metabolic disorder treated by the methods may include obesity, type 2 diabetes mellitus, nonalcoholic fatty liver disease, non-alcoholic steatohepatitis, hyperlipidemia, metabolic syndrome, and cardiovascular disease, hypercholesterolemia, familial hypercholesterolemia, or elevated LDL.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 12, 2022
    Inventors: Douglas E. Vaughan, Joshua A. Levine, Toshio Miyata
  • Patent number: 11253519
    Abstract: The present invention provides a composition effective in improving symptoms of autism spectrum disorder. The composition contains at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof as an active substance. The composition may be used in combination with at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 22, 2022
    Assignee: RENASCIENCE CO., LTD.
    Inventors: Toshio Miyata, Shigeo Kure, Shinichi Kuriyama, Hiroki Sato
  • Publication number: 20210000829
    Abstract: Vitamin B1 deficiency caused when a pyridoxamine compound is administered in a large amount is prevented and/or treated. A pharmaceutical composition formed by combining at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof and at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof, is administered.
    Type: Application
    Filed: July 22, 2020
    Publication date: January 7, 2021
    Applicant: RENASCIENCE CO., LTD.
    Inventor: Toshio MIYATA
  • Publication number: 20200368233
    Abstract: The present invention provides a composition effective in improving symptoms of autism spectrum disorder. The composition contains at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof as an active substance. The composition may be used in combination with at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 2, 2017
    Publication date: November 26, 2020
    Applicant: RENASCIENCE CO., LTD.
    Inventors: Toshio MIYATA, Shigeo KURE, Shinichi KURIYAMA, Hiroki SATO
  • Publication number: 20200149079
    Abstract: Provided are a recombinant microorganism comprising: a gene encoding a pyridoxine oxidase; and a gene encoding a pyridoxamine synthetase having an enzymatic activity of synthesizing pyridoxamine from pyridoxal, in which each of the gene encoding a pyridoxine oxidase and the gene encoding a pyridoxamine synthetase is introduced from outside of a bacterial cell, or is endogenous to the bacterial cell and has an enhanced expression, and a method of producing pyridoxamine or a salt thereof from pyridoxine or a salt thereof using the recombinant microorganism.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 14, 2020
    Applicants: Mitsui Chemicals, Inc., RENASCIENCE CO., LTD
    Inventors: Toshihiro TATENO, Tomonori HIDESAKI, Tadashi ARAKI, Atsunori SHINDO, Yoshiko MATSUMOTO, Toshio MIYATA, Masaru HONJO
  • Publication number: 20200123581
    Abstract: A recombinant microorganism includes a gene encoding a pyridoxine dehydrogenase, a gene encoding a pyridoxamine synthetase having an enzymatic activity of synthesizing pyridoxamine from pyridoxal, and a gene encoding an amino acid regeneration enzyme having an enzymatic activity of regenerating an amino acid consumed by the pyridoxamine synthetase, in which at least two of the gene encoding the pyridoxine dehydrogenase, the gene encoding the pyridoxamine synthetase, or the gene encoding the amino acid regeneration enzyme, are introduced from outside of a bacterial cell, or are endogenous to the bacterial cell and have an enhanced expression. In addition, a recombinant microorganism into which a gene encoding a pyridoxine dehydrogenase is introduced is provided.
    Type: Application
    Filed: May 11, 2018
    Publication date: April 23, 2020
    Applicants: Mitsui Chemicals, Inc., RENASCIENCE CO., LTD
    Inventors: Toshihiro TATENO, Motoi YOKOTA, Tomonori HIDESAKI, Tadashi ARAKI, Atsunori SHINDO, Yoshiko MATSUMOTO, Toshio MIYATA, Masaru HONJO
  • Publication number: 20200046811
    Abstract: The present invention provides compositions, systems, and methods for treating a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23) with a composition comprising: i) an agent that causes an increase in expression of urokinase plasminogen activator (uPA) and/or tissue plasminogen activator (tPA), ii) purified uPA, and/or purified tPA.
    Type: Application
    Filed: March 21, 2019
    Publication date: February 13, 2020
    Inventors: Douglas E. Vaughan, Mesut Eren, Aaron T. Place, Toshio Miyata
  • Patent number: 10092537
    Abstract: Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: October 9, 2018
    Assignee: RENASCIENCE CO., LTD.
    Inventors: Kiyoshi Ando, Takashi Yahata, Toshio Miyata
  • Publication number: 20170258791
    Abstract: Vitamin B1 deficiency caused when a pyridoxamine compound is administered in a large amount is prevented and/or treated. A pharmaceutical composition formed by combining at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof and at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof, is administered.
    Type: Application
    Filed: August 26, 2015
    Publication date: September 14, 2017
    Applicant: PROJECT PM CO., LTD.
    Inventor: Toshio MIYATA
  • Publication number: 20160158188
    Abstract: Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent.
    Type: Application
    Filed: April 15, 2014
    Publication date: June 9, 2016
    Applicant: RENASCIENCE CO., LTD.
    Inventors: Kiyoshi ANDO, Takashi YAHATA, Toshio MIYATA
  • Publication number: 20160144001
    Abstract: The present invention provides compositions, systems, and methods for treating a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23) with a composition comprising: i) an agent that causes an increase in expression of urokinase plasminogen activator (uPA) and/or tissue plasminogen activator (tPA), ii) purified uPA, and/or purified tPA.
    Type: Application
    Filed: November 23, 2015
    Publication date: May 26, 2016
    Inventors: Douglas E. Vaughan, Mesut Eren, Aaron T. Place, Toshio Miyata
  • Publication number: 20140335517
    Abstract: The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.
    Type: Application
    Filed: July 8, 2014
    Publication date: November 13, 2014
    Inventors: Masanari ITOKAWA, Toshio MIYATA, Makoto ARAI
  • Publication number: 20140296256
    Abstract: The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventors: Toshio MIYATA, Kenji MURANO, Nagahisa YAMAOKA, Akihisa MAEDA
  • Patent number: 8809329
    Abstract: The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: August 19, 2014
    Assignees: Tokyo Metropolitan Institute of Medical Science, Renascience Co., Ltd.
    Inventors: Masanari Itokawa, Toshio Miyata, Makoto Arai
  • Patent number: 8785473
    Abstract: The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: July 22, 2014
    Assignee: Renascience Co., Ltd.
    Inventors: Toshio Miyata, Kenji Murano, Nagahisa Yamaoka, Akihisa Maeda
  • Publication number: 20130338574
    Abstract: The present invention provides an oral medicinal composition for peritoneal dialysis patients to suppress an increase of carbonyl compounds and/or advanced glycation/lipoxidation end products (AGEs) in the peritoneal cavity and peritoneal tissue after intraperitoneal administration of a glucose-containing peritoneal dialysis fluid, the oral medicinal composition comprising a pharmaceutically acceptable salt of pyridoxamine as an active ingredient.
    Type: Application
    Filed: July 22, 2011
    Publication date: December 19, 2013
    Applicant: TOKAI UNIVERSITY EDUCATIONAL SYSTEM
    Inventors: Takatoshi Kakuta, Toshio Miyata
  • Patent number: 8415479
    Abstract: The present invention relates to a novel compound having plasminogen activator inhibitor-1 (PAI-1) inhibitory activity, and a PAI-1 inhibitor comprising the compound as an active ingredient. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. The novel compound is represented by the following general formula. Each symbol is defined as those in the specification.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: April 9, 2013
    Assignee: Renascience Co., Ltd.
    Inventors: Toshio Miyata, Nagahisa Yamaoka, Hidehiko Kodama, Kenji Murano
  • Publication number: 20120065198
    Abstract: The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.
    Type: Application
    Filed: July 31, 2008
    Publication date: March 15, 2012
    Applicants: Tokai University Educational System, Tokyo Metropolitan Institute of Medical Science, Renascience Co., Ltd., Medical & Biological Laboratories Co., Ltd.
    Inventors: Masanari ITOKAWA, Toshio MIYATA, Makoto ARAI
  • Publication number: 20120022080
    Abstract: The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.
    Type: Application
    Filed: March 31, 2010
    Publication date: January 26, 2012
    Applicant: RENASCIENCE CO., LTD.
    Inventors: Toshio Miyata, Kenji Murano, Nagahisa Yamaoka, Akihisa Maeda
  • Patent number: 7951806
    Abstract: The present invention relates to an inhibitor of plasminogen activator inhibitor-1. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. Furthermore, the present invention relates to a novel compound having PAI-1 inhibitory activity represented by the following general formula (I), and a salt thereof. Each symbol is defined as those in the specification.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: May 31, 2011
    Assignee: Renascience Co., Ltd.
    Inventors: Toshio Miyata, Nagahisa Yamaoka, Hidehiko Kodama